From JAMA |

Sample Tracking and Use in Published Genome-wide Association Studies

John Hardy, PhD
Arch Neurol. 2010;67(10):1267-1268. doi:10.1001/archneurol.2010.251.
Text Size: A A A
Published online



Genome-wide Analysis of Genetic Loci Associated With Alzheimer Disease

Sudha Seshadri, MD; Annette L. Fitzpatrick, PhD; M. Arfan Ikram, MD, PhD; Anita L. DeStefano, PhD; Vilmundur Gudnason, MD, PhD; Merce Boada, MD, PhD; Joshua C. Bis, PhD; Albert V. Smith, PhD; Minerva M. Carrasquillo, PhD; Jean Charles Lambert, PhD; Denise Harold, PhD; Elisabeth M. C. Schrijvers, MD; Reposo Ramirez-Lorca, PhD; Stephanie Debette, MD, PhD; W. T. Longstreth Jr, MD; A. Cecile J. W. Janssens, PhD; V. Shane Pankratz, PhD; Jean François Dartigues, PhD; Paul Hollingworth, PhD; Thor Aspelund, PhD; Isabel Hernandez, MD; Alexa Beiser, PhD; Lewis H. Kuller, MD; Peter J. Koudstaal, MD, PhD; Dennis W. Dickson, MD; Christophe Tzourio, MD; Richard Abraham, PhD; Carmen Antunez, MD; Yangchun Du, PhD; Jerome I. Rotter, MD; Yurii S. Aulchenko, PhD; Tamara B. Harris, MD; Ronald C. Petersen, MD; Claudine Berr, MD, PhD; Michael J. Owen, MbChB, PhD; Jesus Lopez-Arrieta, MD; Badri N. Vardarajan, MS; James T. Becker, PhD; Fernando Rivadeneira, MD, PhD; Michael A. Nalls, PhD; Neill R. Graff-Radford, MD; Dominique Campion, MD, PhD; Sanford Auerbach, MD; Kenneth Rice, PhD; Albert Hofman, MD, PhD; Palmi V. Jonsson, MD; Helena Schmidt, MD, PhD; Mark Lathrop, PhD; Thomas H. Mosley, PhD; Rhoda Au, PhD; Bruce M. Psaty, MD, PhD; Andre G. Uitterlinden, PhD; Lindsay A. Farrer, PhD; Thomas Lumley, PhD; Agustin Ruiz, MD, PhD; Julie Williams, PhD; Philippe Amouyel, MD, PhD; Steve G. Younkin, PhD; Philip A. Wolf, MD; Lenore J. Launer, PhD; Oscar L. Lopez, MD; Cornelia M. van Duijn, PhD; Monique M. B. Breteler, MD, PhD; for the CHARGE, GERAD1, and EADI1 Consortia

Context:  Genome-wide association studies (GWAS) have recently identified CLU, PICALM, and CR1 as novel genes for late-onset Alzheimer disease (AD).

Objectives:  To identify and strengthen additional loci associated with AD and confirm these in an independent sample and to examine the contribution of recently identified genes to AD risk prediction in a 3-stage analysis of new and previously published GWAS on more than 35 000 persons (8371 AD cases).

Design, Setting, and Participants:  In stage 1, we identified strong genetic associations (P < 10−3) in a sample of 3006 AD cases and 14 642 controls by combining new data from the population-based Cohorts for Heart and Aging Research in Genomic Epidemiology consortium (1367 AD cases [973 incident]) with previously reported results from the Translational Genomics Research Institute and the Mayo AD GWAS. We identified 2708 single-nucleotide polymorphisms (SNPs) with P < 10−3. In stage 2, we pooled results for these SNPs with the European AD Initiative (2032 cases and 5328 controls) to identify 38 SNPs (10 loci) with P < 10−5. In stage 3, we combined data for these 10 loci with data from the Genetic and Environmental Risk in AD consortium (3333 cases and 6995 controls) to identify 4 SNPs with P < 1.7 × 10−8. These 4 SNPs were replicated in an independent Spanish sample (1140 AD cases and 1209 controls). Genome-wide association analyses were completed in 2007-2008 and the meta-analyses and replication in 2009.

Main Outcome Measure:  Presence of Alzheimer disease.

Results:  Two loci were identified to have genome-wide significance for the first time: rs744373 near BIN1 (odds ratio [OR], 1.13; 95% confidence interval [CI], 1.06-1.21 per copy of the minor allele; P = 1.59 × 10−11) and rs597668 near EXOC3L2/BLOC1S3/MARK4 (OR, 1.18; 95% CI, 1.07-1.29; P = 6.45 × 10−9). Associations of these 2 loci plus the previously identified loci CLU and PICALM with AD were confirmed in the Spanish sample (P < .05). However, although CLU and PICALM were confirmed to be associated with AD in this independent sample, they did not improve the ability of a model that included age, sex, and APOE to predict incident AD (improvement in area under the receiver operating characteristic curve from 0.847 to 0.849 in the Rotterdam Study and 0.702 to 0.705 in the Cardiovascular Health Study).

Conclusions:  Two genetic loci for AD were found for the first time to reach genome-wide statistical significance. These findings were replicated in an independent population. Two recently reported associations were also confirmed. These loci did not improve AD risk prediction. While not clinically useful, they may implicate biological pathways useful for future research.

JAMA. 2010;303(18):1832-1840.


Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours





Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment


Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.